ASX:HLA

Stock Analysis Report

Executive Summary

Healthia Limited provides health services in Australia.

Snowflake

Fundamentals

High growth potential with imperfect balance sheet.

Share Price & News

How has Healthia's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

12.6%

HLA

1.6%

AU Healthcare

1.0%

AU Market


1 Year Return

-16.9%

HLA

18.0%

AU Healthcare

11.7%

AU Market

Return vs Industry: HLA underperformed the Australian Healthcare industry which returned 18% over the past year.

Return vs Market: HLA underperformed the Australian Market which returned 11.7% over the past year.


Shareholder returns

HLAIndustryMarket
7 Day12.6%1.6%1.0%
30 Day8.9%1.7%-0.2%
90 Day8.9%-1.3%0.3%
1 Year-16.9%-16.9%21.7%18.0%18.1%11.7%
3 Yearn/a3.6%-5.8%37.4%19.0%
5 Yearn/a46.9%26.2%51.7%17.6%

Price Volatility Vs. Market

How volatile is Healthia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Healthia undervalued compared to its fair value and its price relative to the market?

1.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: HLA (A$0.98) is trading above our estimate of fair value (A$0.63)

Significantly Undervalued: HLA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HLA is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: HLA is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate HLA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HLA is good value based on its PB Ratio (1.5x) compared to the AU Healthcare industry average (1.6x).


Next Steps

Future Growth

How is Healthia forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

54.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: HLA is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: HLA's loss is forecast to worsen by 0% next year.

Revenue vs Market: HLA's revenue (23.6% per year) is forecast to grow faster than the Australian market (3.5% per year).

High Growth Revenue: HLA's revenue (23.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: HLA's Return on Equity is forecast to be low in 3 years time (11.8%).


Next Steps

Past Performance

How has Healthia performed over the past 5 years?

38.3%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HLA is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare HLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-1.7%).


Return on Equity

High ROE: HLA has a negative Return on Equity (-0.55%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: HLA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: HLA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Healthia's financial position?


Financial Position Analysis

Short Term Liabilities: HLA's short term assets (A$10.7M) exceeds its short term liabilities (A$9.5M)

Long Term Liabilities: HLA's short term assets (10.7M) do not cover its long term liabilities (22.5M)


Debt to Equity History and Analysis

Debt Level: HLA's debt to equity ratio (38.7%) is considered satisfactory

Reducing Debt: Insufficient data to determine if HLA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: HLA has a low level of unsold assets or inventory.

Debt Coverage by Assets: HLA's debt is not covered by short term assets (assets are 0.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HLA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HLA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -220.8% each year


Next Steps

Dividend

What is Healthia's current dividend yield, its reliability and sustainability?

5.78%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%2.5%markettop25%5.6%industryaverage2.9%forecastin3Years5.8%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HLA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HLA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HLA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Healthia's salary, the management and board of directors tenure and is there insider trading?

0.5yrs

Average management tenure


CEO

Wes Coote 0

0.5yrs

Tenure

0

Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at  ...


Management Age and Tenure

0.5yrs

Average Tenure

Experienced Management: HLA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Age and Tenure

1.4yrs

Average Tenure

Experienced Board: HLA's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: HLA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyAU$20,65505 Sep 19
Lisa Dalton
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares22,500
Max PriceAU$0.92
BuyAU$299,90725 Jun 19
Glen Richards
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares365,670
Max PriceAU$0.82
BuyAU$270,08126 Mar 19
Glen Richards
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares300,090
Max PriceAU$0.90

Ownership Breakdown


Management Team

  • Wes Coote

    Group MD

    • Tenure: 0.5yrs
  • Greg Dower

    Chief Business Development Officer

    • Tenure: 0yrs
  • Dean Hartley

    Chief Information Officer

    • Tenure: 0yrs
  • Glen Evangelista

    Group Chief Commercial Officer

    • Tenure: 0.5yrs
  • Darren Stewart

    CEO of Podiatry & Executive Director

    • Tenure: 1.4yrs
  • Tony Ganter

    CEO of Physiotherapy & Executive Director

    • Tenure: 0yrs
  • Lisa Roach

    Chief Operating Officer of Physiotherapy

    • Tenure: 0yrs
  • Chris Banks

    Group CFO & Company Secretary

    • Tenure: 0.5yrs
  • Kerrie Evans

    Group Chief Education & Research Officer

    • Tenure: 0yrs

Board Members

  • Glen Richards

    Non-Executive Chairman

    • Tenure: 1.4yrs
  • Wes Coote

    Group MD

    • Tenure: 0.5yrs
  • Paul Wilson

    Independent Non-Executive Director

    • Tenure: 1.4yrs
  • Lisa Dalton

    Independent Non-Executive Director

    • Tenure: 1.4yrs
  • Darren Stewart

    CEO of Podiatry & Executive Director

    • Tenure: 1.4yrs
  • Tony Ganter

    CEO of Physiotherapy & Executive Director

    • Tenure: 0yrs

Company Information

Healthia Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Healthia Limited
  • Ticker: HLA
  • Exchange: ASX
  • Founded: 2018
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$55.786m
  • Shares outstanding: 63.03m
  • Website: https://www.healthia.com.au

Location

  • Healthia Limited
  • East Tower
  • Level 4
  • Bowen Hills
  • Queensland
  • 4006
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HLAASX (Australian Securities Exchange)YesOrdinary SharesAUAUDSep 2018
HLACHIA (Chi-X Australia)YesOrdinary SharesAUAUDSep 2018

Biography

Healthia Limited provides health services in Australia. The company operates 72 podiatry clinics under the My FootDr brand; 23 physiotherapy clinics under the Allsports Physiotherapy brand; and 7 hand ther ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 10:42
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.